Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0043

Advisory board · Dr. Farah Garcia

03 Aug 2026 · In person · Dr. Farah Garcia, Hôpital Pitié-Salpêtrière · MSL James Whitfield · Vantrexa

ReviewedManualENG-0043—

Capture insight from this engagement

Location: Hôpital Pitié-Salpêtrière
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Comparator checkpoint monotherapy

Scientific content used

PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Advisory board with pathologist at Hôpital Pitié-Salpêtrière. Discussed sequencing after progression, comparator checkpoint monotherapy.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 1
Actionability: 5

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0043

Audit history (0)

All create, update and approval events for this record

No audit events in sample data